Study Aims to Curb Asthma Over-Medication

NBC published an article covering new research currently being carried out by Dr. John Mastronarde and his team at the Ohio State Medical Center. The study aims to find the optimal amount of medication for each asthma patient. This research is essential in the asthma medication space due to over-medication creating unnecessary costs and health hazards. The study will examine combinations of inhalers and medicines to find the most effective dose levels at various situations.

“With 26 million Americans taking asthma medicines at a cost of $150 million a day, a new study seeks to determine how to change the fact that many of those patients are taking too much medicine.

Dr. John Mastronarde and his colleagues at Ohio State University Medical Center are researching how to get patients on the lowest dose of asthma medicine possible.

He said the drugs can cost patients between $3 and $500 per month.

Studies have found that cost may increase during acute attacks since patients increase the use of medication and inhalers to combat symptoms then continuing using those elevated doses after the attack.

Mastronarde said many asthma patients take more medicine than they need and though official guidelines suggest steadily tapering the dosage to the right amount, none have a proven successful way of weaning patients.

The study out of Ohio will examine medicines and inhalers to determine which combinations at which dose is best under which circumstances.

While some patients take too many medicines, increasing their risk of side effects, others avoid preventive treatments altogether because of the high costs. This study may reduce risks for some patients and may reduce hospitalizations and the danger of severe attacks in the future for others.

All patients who have asthma should get regular checkups to determine the lowest, and least costly dose of medication that is right for them.”

Check out the article here

Geckocap is a better method to manage your child’s asthma medication. Find out more here